Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ira Gantz

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Diabetes, Obesity & Metabolism|November 6, 2018
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I StudyRonan Roussel, Santiago Duran-García, Yilong Zhang, et al.
The Journal of Biological Chemistry|January 10, 2002
Food deprivation-induced expression of minoxidil sulfotransferase in the hypothalamus uncovered by microarray analysisJi-Yao Li, Pascal A Lescure, David E Misek, et al.
Obesity (Silver Spring, Md.)|April 10, 2010
A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie dietThomas A Wadden, Ken Fujioka, Soren Toubro, et al.
The Journal of Clinical Endocrinology and Metabolism|March 8, 2007
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adultsIra Gantz, Ngozi Erondu, Madhuja Mallick, et al.
European Heart Journal|October 21, 2023
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trialAmbarish Pandey, Ahmed A Kolkailah, Francesco Cosentino, et al.
JAMA Cardiology|October 8, 2020
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysisDarren K McGuire, Weichung J Shih, Francesco Cosentino, et al.
Circulation|October 7, 2020
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV TrialFrancesco Cosentino, Christopher P Cannon, David Z I Cherney, et al.
The New England Journal of Medicine|September 23, 2020
Cardiovascular Outcomes with Ertugliflozin in Type 2 DiabetesChristopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, et al.
European Journal of Heart Failure|January 10, 2025
Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trialAmbarish Pandey, Ahmed A Kolkailah, Darren K McGuire, et al.
Obesity (Silver Spring, Md.)|August 23, 2007
NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramineNgozi Erondu, Carol Addy, Kaifeng Lu, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Diabetes, Obesity & Metabolism|November 6, 2018
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I StudyRonan Roussel, Santiago Duran-García, Yilong Zhang, et al.
The Journal of Biological Chemistry|January 10, 2002
Food deprivation-induced expression of minoxidil sulfotransferase in the hypothalamus uncovered by microarray analysisJi-Yao Li, Pascal A Lescure, David E Misek, et al.
Obesity (Silver Spring, Md.)|April 10, 2010
A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie dietThomas A Wadden, Ken Fujioka, Soren Toubro, et al.
The Journal of Clinical Endocrinology and Metabolism|March 8, 2007
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adultsIra Gantz, Ngozi Erondu, Madhuja Mallick, et al.
European Heart Journal|October 21, 2023
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trialAmbarish Pandey, Ahmed A Kolkailah, Francesco Cosentino, et al.
JAMA Cardiology|October 8, 2020
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysisDarren K McGuire, Weichung J Shih, Francesco Cosentino, et al.
Circulation|October 7, 2020
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV TrialFrancesco Cosentino, Christopher P Cannon, David Z I Cherney, et al.
The New England Journal of Medicine|September 23, 2020
Cardiovascular Outcomes with Ertugliflozin in Type 2 DiabetesChristopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, et al.
European Journal of Heart Failure|January 10, 2025
Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trialAmbarish Pandey, Ahmed A Kolkailah, Darren K McGuire, et al.
Obesity (Silver Spring, Md.)|August 23, 2007
NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramineNgozi Erondu, Carol Addy, Kaifeng Lu, et al.
Pageof 7